Analytical Data
-
Gene name
CNR2
- Application
-
Alternative Names
CNR2；CB2A；CB2B；Cannabinoid receptor 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P34972
-
Expression Region
1-360aa
-
AA Sequence
MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALE NVAVLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGV DSKAVFLLKIGSVTMTFTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRA LVTLGIMWVLSALVSYLPLMGWTCCPRPCSELFPLIPNDYLLSWLLFIAF LFSGIIYTYGHVLWKAHQHVASLSGHQDRQVPGMARMRLDVRLAKTLGLV LAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYA LRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWP DSRDLDLSDC
-
Molecular Weight
66 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CNR2, also known as the cannabinoid receptor type 2, is a G protein-coupled receptor that plays a crucial role in the endocannabinoid system, which regulates various physiological processes, including pain sensation, inflammation, and immune response. Unlike its counterpart CNR1, which is predominantly expressed in the brain, CNR2 is primarily found in peripheral tissues, suggesting its significant involvement in immune modulation and potential therapeutic applications. Given the increasing interest in cannabinoids for therapeutic purposes, particularly in the context of chronic pain and neurodegenerative diseases, research on CNR2 and its recombinant proteins has gained momentum. Recombinant CNR2 proteins are essential for elucidating the receptor's structure, function, and signaling mechanisms, providing insights into ligand-receptor interactions, and facilitating the development of selective CNR2 agonists or antagonists. Such studies may pave the way for novel treatments targeting CNR2 in various pathologies, including autoimmune disorders and inflammatory diseases. The production and characterization of recombinant CNR2 proteins can also contribute to the understanding of receptor pharmacology and the potential for drug discovery, establishing CNR2 as a promising target in the pharmacological landscape.
